ELEduardo de Paiva Luciano

Eduardo de Paiva Luciano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eduardo de Paiva Luciano has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nefropatia por IgA: estratégias de tratamento em evolução

    by Gianna Mastroianni-Kirsztajn, Juliana Mansur Siliano, Eduardo de Paiva Luciano

    RESUMO A nefropatia por IgA é considerada a mais frequente entre as doenças glomerulares, tem apresentações clínico-laboratoriais e histopatológicas bastante diversas e potencial de progressão para estágios avançados de DRC conforme diversas características subjacentes. O maior conhecimento da sua patogênese, que envolve pelo menos uma sequência de 4 fatores desencadeantes principais, possibilitou o desenvolvimento de alternativas terapêuticas, que podem atuar em diferentes etapas de sua gênese, inclusive fármacos direcionados a alvos específicos ao longo desse processo. Já está bem definido que as medidas ditas renoprotetoras são essenciais para o tratamento de suporte, envolvendo modificação no estilo de vida (dieta saudável, exercícios físicos, controle de peso, cessação do tabagismo, restrição de sódio, controle da pressão arterial e medidas para redução do risco cardiovascular) e uso de fármacos, entre os quais devem ser mencionados: inibidores do SRAA e do SGLT2, antagonistas do receptor de mineralocorticoide e do receptor de endotelina A. Os recursos imunossupressores concentraram-se no passado, sobretudo, no uso de corticosteroide sistêmico, aliado à ciclofosfamida ou à azatioprina em situações especiais. Mais recentemente, surgiu a budesonida de liberação entérica, seguindo-se o desenvolvimento de fármacos direcionados a vias moleculares específicas, entre os quais se destacam os inibidores do complemento e aqueles direcionados à sinalização BAFF e/ou APRIL, entre outros. Essa diversidade de medicamentos gera oportunidades, mas também dúvidas e desafios por ocasião da tomada de decisão, exigindo definição de parâmetros que guiem a seleção das opções terapêuticas e suas combinações em prol do melhor resultado para o paciente, diante dos diferentes endótipos dessa glomerulopatia.

  • IgA nephropathy: evolving treatment strategies

    by Gianna Mastroianni-Kirsztajn, Juliana Mansur Siliano, Eduardo de Paiva Luciano

    IgA nephropathy (IgAN) is the most common primary glomerular disease and is characterized by marked clinical, laboratory, and histopathological heterogeneity, with a variable risk of progression to advanced stages of chronic kidney disease depending on several underlying factors. A better understanding of its pathogenesis, which involves at least a four-hit pathogenic sequence, has enabled the development of novel therapeutic strategies targeting different stages of disease development, including agents directed at specific molecular pathways. Supportive kidney-protective therapy is now well established as the cornerstone of IgAN management and involves lifestyle modifications such as a healthy diet, regular physical activity, weight control, smoking cessation, sodium restriction, optimal blood pressure control, and interventions to reduce cardiovascular risk. Pharmacological measures include renin-angiotensin-aldosterone system and sodium-glucose cotransporter 2 (SGLT2) inhibitors, as well as mineralocorticoid receptor and endothelin A receptor antagonists. Historically, immunosuppressive treatment relied primarily on systemic corticosteroids, with cyclophosphamide or azathioprine reserved for selected clinical situations. More recently, targeted-release budesonide has emerged as a therapeutic option, followed by the development of agents directed at specific molecular pathways, particularly complement inhibitors and therapies targeting BAFF and/or APRIL signaling, among others. Although this expanding therapeutic armamentarium provides new opportunities to improve patient outcomes, it also introduces uncertainty and complexity into clinical decision-making. Therefore, defining evidence-based parameters to guide the selection and combination of available therapies according to the distinct endotypes of IgAN has become increasingly important.

  • Open Access

    BRIGHT-HD—A Brazilian Research Investigation on Public Health Gains Comparing Survival Rates Between Hemodialysis and Hemodiafiltration: An Observational Study

    by Eduardo P. Luciano, João Chang, Elaine C. S. Arantes, Aline Cordeiro, Sandra F. S. Reis, Douglas V. Andrade, Whelington F. Rocha, Andrea O. Magalhães, Cynthia M. Borges, Rosilene M. Elias

    Background/Objectives: High-flux online hemodiafiltration (OL-HDF) appears to be associated with better survival than hemodialysis (HD). In Brazil, OL-HDF is only affordable for patients with private health insurance. Although observational studies have shown a survival advantage with OL-HDF, even in Brazil, it is unclear whether this benefit applies to patients without private health insurance. We compared overall and cardiovascular mortality between OL-HDF and HD in patients treated exclusively through the public health care system. We hypothesized that patients on OL-HDF would have a higher survival rate than those on HD. Methods: This is an observational cohort study. Adult patients on maintenance hemodialysis or OL-HDF for at least one month during the period between 1 September 2022 and 1 December 2024 were enrolled into the study. The primary outcome was all-cause mortality. The secondary outcome was cardiovascular mortality. Fine-Gray sub-distribution hazard models were used to evaluate survival in the presence of competing events (kidney transplant and recovery of renal function). Results: Patients on HD (N = 321) and OL-HDF (N = 48) were similar in age, race, sex, and vascular access. Patients on HD were more likely to have diabetes (54.0% vs. 29.2%, p = 0.001) and spent more hours per week on dialysis (11.2 ± 1.8 vs. 10.5 ± 1.6 h, p = 0.006). In an adjusted Fine-Gray model, the hazard of death for patients on OL-HDF was 68% lower than that for patients on HD, and the risk of death for patients with an arteriovenous fistula was 55% lower compared to those with a catheter. Cardiovascular mortality did not differ between the groups. Conclusions: These findings suggest that OL-HDF is associated with an overall higher survival rate compared to HD, even for patients without private health insurance.


  • Open Access

    Treatment of hypercalcemia related to polymethylmethacrylate injection: report of three cases

    by Lívia Reis de Miranda, Eduardo de Paiva Luciano, Eduarda Andrea Silva Rizzo, Marissol Fernandes Oliveira, Sheila Cavalca Cortelli, Walnei Fernandes Barbosa

    Polymethylmethacrylate is a microsphere-based plastic used in aesthetic procedures. However, it can cause granuloma formation and severe hypercalcemia, often accompanied by renal impairment, which is a significant concern. Despite increasing reports, there is no standardized treatment approach for polymethylmethacrylate-induced hypercalcemia, and its incidence remains underreported. In this study, we present three cases of polymethylmethacrylate users who developed severe hypercalcemia that was resistant to conventional treatments, resulting in deteriorating renal function. These patients achieved symptom control with cinacalcet, a medication


  • Open Access

    BRIGHT-HD – Brazil Research Investigation on Public Health Gain Comparing Survival Between Hemodialysis and Hemodiafiltration, an Observational Study

    by Eduardo P Luciano, Joao Chang, Elaine C.S. Arantes, Aline Cordeiro, Sandra F.S. Reis, Douglas V Andrade, Whelington F Rocha, Andrea O. Magalhaes, Cynthia M. Borges, Rosilene M Elias

    Background/Objectives: High-flux online hemodiafiltration (OL-HDF) appears to be associated with better survival than hemodialysis (HD). In Brazil, OL-HDF is only affordable for patients with private health insurance. Although observational studies have shown a survival advantage with OL-HDF, even in Brazil, it is unclear whether this benefit applies to patients without private health insurance. We compared overall and cardiovascular mortality between OL-HDF and HD in patients treated exclusively through the Public Health Care system. We hypothesize that patients on OL-HDF will have a higher survival rate than those on HD. Methods: This is an observational cohort study. Adult patients on maintenance hemodialysis or OL-HDF for at least one month during the period between September 1, 2022, and December 1, 2024. The primary outcome was all-cause mortality. The secondary outcome was cardiovascular mortality. Fine-Gray sub-distribution hazard models were used to evaluate survival in the presence of competing events (kidney transplant and recovery of renal function). Results: Patients on HD (N=321) and OL-HDF (N=48) were similar in age, race, sex, and vascular access. Patients on HD were more likely to have diabetes (54.0% vs. 29.2%, p=0.001) and spent more hours per week on dialysis (11.2 ± 1.8 vs. 10.5 ± 1.6 hours, p=0.006). In an adjusted Fine-Gray model, the hazard of death for patients on OL-HDF was 68% lower than that for patients on HD, and the risk of death for patients with an arteriovenous fistula was 55% lower compared to those with a catheter. Cardiovascular mortality did not differ between the groups. Conclusions: These findings suggest that OL-HDF is associated with higher overall survival compared to HD, even for patients without private health insurance.

  • Open Access

    Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV

    by Gustavo Ferreira da Mata, Danilo Euclides Fernandes, Eduardo de Paiva Luciano, Gabriel Teixeira Montezuma Sales, Michelle Tiveron Passos Riguetti, Gianna Mastroianni Kirsztajn

    Inflammation is closely related to renal diseases. This is particularly true for renal diseases caused by infections as in viral diseases. In this review, we highlight the inflammatory mechanisms that underlie kidney dysfunction in SARS-CoV-2, human immunodeficiency (HIV), hepatitis C (HCV), and hepatitis B (HBV) infections. The pathophysiology of renal involvement in COVID-19 is complex, but kidney damage is frequent, and the prognosis is worse when it happens. Virus-like particles were demonstrated mostly in renal tubular epithelial cells and podocytes, which suggest that SARS-CoV-2 directly affects the kidneys. SARS-CoV-2 uses the angiotensin-converting enzyme 2 receptor, which is found in endothelial cells, to infect the human host cells. Critical patients with SARS-CoV-2-associated acute kidney injury (AKI) show an increase in inflammatory cytokines (IL-1β, IL-8, IFN-γ, TNF-α), known as cytokine storm that favors renal dysfunction by causing intrarenal inflammation, increased vascular permeability, volume depletion, thromboembolic events in microvasculature and persistent local inflammation. Besides AKI, SARS-CoV-2 can also cause glomerular disease, as other viral infections such as in HIV, HBV and HCV. HIV-infected patients present chronic inflammation that can lead to a number of renal diseases. Proinflammatory cytokines and TNF-induced apoptosis are some of the underlying mechanisms that may explain the virus-induced renal diseases that are here reviewed.